… No firm conclusion can be taken with the lower dabigatran etexilate dosage (110 mg BID)
because of the limited number of studies. However, a trend toward an increased risk of MI (33%…

… collection in the present study could predict the bleeding outcome, serial dabigatran
etexilate-HTI measurement might provide an even better predictive value. The routine coagulation …

… [19,20] The primary efficacy outcome was a composite … [19,20] Secondary efficacy outcomes
included a composite of major … sodium, focusing on the occurrence of bleeding[19,20] and …

… not result in a consistent effect on the relative risk of bleeding or a statistically significant effect
on the relative efficacy of either dose of dabigatran etexilate … rifampin, dabigatran exposure …

… bleeding events constituted safety outcomes in all studies but there was no uniform definition
of these events. Major bleeding … rates of periprocedural bleeding of dabigatran and warfarin…

… and bleeding outcomes associated with dabigatran etexilate versus warfarin administered
for the prevention of stroke or systemic embolism in nonvalvular atrial fibrillation. Results from …

… of major bleeding between treatments; however, dabigatran was … In addition, dabigatran
etexilate mesylate, 150 mg, was … Our results for gastrointestinal and intracranial bleeding are …

… Overall, results of several studies demonstrate dabigatran etexilate’s rapid onset of effect, …
in the frequency of major bleeding events between either dabigatran etexilate 220 mg (p=0.44) …

… higher rates of major bleeding. This study also found that dabigatran etexilate 150 mg twice
daily … difference in any bleeding outcomes between either of the dabigatran groups and the …

… We found no evidence of an excess of bleeding events or MI among dabigatran-treated patients
in this propensity-… The outcomes addressed in this study cover hospital diagnosis (major …